A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
VTV celebrates a double positive
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
Tirzepatide’s time to shine for Lilly
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Upcoming events – Adamas and Ascendis look for new paths forward
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
